These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26083554)

  • 1. In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells.
    Boks MA; Bruijns SCM; Ambrosini M; Kalay H; van Bloois L; Storm G; Gruijl T; van Kooyk Y
    J Invest Dermatol; 2015 Nov; 135(11):2697-2704. PubMed ID: 26083554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses.
    Boks MA; Ambrosini M; Bruijns SC; Kalay H; van Bloois L; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Oct; 216():37-46. PubMed ID: 26151293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ Delivery of Antigen to DC-SIGN(+)CD14(+) Dermal Dendritic Cells Results in Enhanced CD8(+) T-Cell Responses.
    Fehres CM; van Beelen AJ; Bruijns SCM; Ambrosini M; Kalay H; Bloois LV; Unger WWJ; Garcia-Vallejo JJ; Storm G; de Gruijl TD; Kooyk YV
    J Invest Dermatol; 2015 Sep; 135(9):2228-2236. PubMed ID: 25885805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
    Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
    Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
    Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
    J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.
    Stolk DA; de Haas A; Vree J; Duinkerken S; Lübbers J; van de Ven R; Ambrosini M; Kalay H; Bruijns S; van der Vliet HJ; de Gruijl TD; van Kooyk Y
    Front Immunol; 2020; 11():990. PubMed ID: 32536918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
    Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
    Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
    Cioca DP; Deak E; Cioca F; Paunescu V
    J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
    Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
    J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
    Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
    J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.
    Duinkerken S; Horrevorts SK; Kalay H; Ambrosini M; Rutte L; de Gruijl TD; Garcia-Vallejo JJ; van Kooyk Y
    Theranostics; 2019; 9(20):5797-5809. PubMed ID: 31534520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8(+) T Cells.
    Maji M; Mazumder S; Bhattacharya S; Choudhury ST; Sabur A; Shadab M; Bhattacharya P; Ali N
    Sci Rep; 2016 Jun; 6():27206. PubMed ID: 27251373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic and Functional Properties of Human Steady State CD14+ and CD1a+ Antigen Presenting Cells and Epidermal Langerhans Cells.
    Fehres CM; Bruijns SC; Sotthewes BN; Kalay H; Schaffer L; Head SR; de Gruijl TD; Garcia-Vallejo JJ; van Kooyk Y
    PLoS One; 2015; 10(11):e0143519. PubMed ID: 26605924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
    von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
    J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective tumor antigen vaccine delivery to human CD169
    Affandi AJ; Grabowska J; Olesek K; Lopez Venegas M; Barbaria A; Rodríguez E; Mulder PPG; Pijffers HJ; Ambrosini M; Kalay H; O'Toole T; Zwart ES; Kazemier G; Nazmi K; Bikker FJ; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Storm G; van Kooyk Y; den Haan JMM
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27528-27539. PubMed ID: 33067394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.